GeoVax Labs, Inc. announced that it will be represented during presentations at the following upcoming European scientific conferences.
Unique Platform Continues to be Recognized for Distinct Benefits
ATLANTA, GA, October 15, 2019 – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today that it will be represented during presentations at the following upcoming European scientific conferences.
Festival of Biologics / World Immunotherapy Congress, Basel, Switzerland, Oct. 15-17
Farshad Guirakhoo, PhD, GeoVax Chief Scientific Officer, will deliver an oral presentation entitled, Utilizing a Live Modified Vaccinia Ankara Virus to Deliver Cancer Antigens in Highly Immunogenic Forms of Virus Like Particles. In this talk, Dr. Guirakhoo will illustrate advantages of the inherently safe MVA-VLP platform to deliver “cancer like MUC1” antigens designed to break the host tolerance against MUC1 and train the body’s own immune system to attack and kill cancer cells.
International Society for Virology (ISV), 2019 Annual Congress, Ghent, Belgium, Oct. 27-29
During this conference, Dr. Guirakhoo will deliver an oral presentation entitled, Development of Single Dose Vaccines against Emerging and Reemerging Infectious Diseases Using a Novel MVA‐VLP Vector. In this talk, latest data for Ebola, Marburg, Lassa and Zika vaccines, pathogens selected from three different families of viruses, will demonstrate broad utility of GeoVax’s vector platform for developing safe and effective single-dose vaccines for many known emerging and re-emerging infectious diseases.
World Vaccine Congress-Europe, Barcelona, Spain, Oct. 29-31
During this conference, Dr. Guirakhoo will deliver an oral presentation entitled, MVA-VLP as a safe and effective platform for delivery of multi-antigen vaccine candidates for infectious diseases and cancer. In this talk, the most relevant vaccine safety and efficacy data, including characterization of humoral and T cell responses, for selected viral infectious disease targets will be presented as examples for a broad utility of the platform for other indications such as malaria, HPV, HBV and cancer immunotherapy.
Commenting on these presentations, David Dodd, GeoVax CEO stated, “We are pleased in the continued and increasing recognition of the GeoVax MVA-VLP technology and expertise, ranging from immuno-oncology to various infectious diseases. Such invited presentations provide us the opportunity to further underscore the potential value of our developments focused on improving the lives of millions worldwide, while also progressing our collaboration discussions with both public and private organizations.”
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.
GeoVax’s current development programs are focused on preventive vaccines against HIV, Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against chronic Hepatitis B infections, HPV and multiple solid tumor cancers. The Company has designed the leading preventative HIV vaccine candidate to fight against the subtype of HIV prevalent in the larger commercial markets of the Americas, Western Europe, Japan, and Australia; this program is currently undergoing human clinical trials managed by the HIV Vaccine Trials Network (HVTN) with the support of the National Institutes of Health (NIH). GeoVax’s HIV vaccine is also part of collaborative efforts to develop an immunotherapy as a functional cure for HIV. For more information, visit www.geovax.com.
Contact:
GeoVax Labs, Inc.
678-384-7220
